DR NO DR-XY25335 BR-806 DR-XY29805 DR-XY38246 DR-XY29154 DR-XY29301 DR-XY38247 DR-XY32261 DR-XY37776 DR-XY15242 DR-XY28585 DR-XY35412 DRP-2205-01 DRP-2205 DR-XY34264 DR-XY25262…

1. ANEMIA Prof. M A Bakr (MD) Urology & Nephrology Center Mansoura University - Egypt 2. I. Anemia and kidney II. Biosimilars III. Recommendations AGENDA 3. I. Anemia…

1. Presentation ofNEJM Article on Efficacy & Safety of Epoetin Alfa in Critically Ill Patients William C Lambert, M.D. 2. Original Article Efficacy and Safety of Epoetin…

1. Code for Documentation! Audit for Compliance! Richard J Hamburger MD Professor Emeritus of Medicine Indiana University Indianapolis IN Debra H. Lawson, CPC, PCS Nephrology…

Slide 1Breaking the Vicious Cycle – Efficacy of Anemia Therapies Peter Bárány Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska…

1.CHRONIC RENAL FAILURE YOUAN BI BENIET MARIUS. PHARM D, MASTER OF CLINICAL PHARMACY. UNIVERSITY OF NAIROBI 2. OUTLINES DEFINITION ETIOLOGY and PATHOGENESIS PATHOPHYSIOLOGY…

No. 1, 2002 EDITORIAL In November 2001 the 24th Annual Meeting of the National Centres participating in the WHO Programme for International Drug Monitoring met in Dunedin,…

Slide 1 Challenges and its Resolution in Biosimilar Clinical Development Chirag Shah Ph.D,PGDPM Asso.Director & Head-Clinical Trials Cliantha Research Ltd 27 Oct 2014…

1-  cell repair mechanisms: e.g.  DNA repair causing resistance to alkylating agents 2-  inactivation of the drug by enzymes (purine & pyrimidine antimetabolites)…

Pharmacovigilance in the Post-Marketing Setting: Results from the RADAR Project Charles L. Bennett MD PhD MPP Barriers to Identifying Adverse Events Limited size of clinical…